Skip to main content

Table 3 Participants reporting at least one serious adverse event from Day 0 to Day 179 in the total vaccinated cohort

From: Selection of an adjuvant for seasonal influenza vaccine in elderly people: modelling immunogenicity from a randomized trial

  AS03C AS03C-MPL25 AS03C-MPL50 AS03B AS03B-MPL25 AS03B-MPL50 AS03A AS03A-MPL25 Non-adjuvanted ≥65 y Non-adjuvanted 18–40 y
  N=204 N=202 N=198 N=202 N=199 N=199 N=202 N=198 N=200 N=203
Day 0–21 0 (0.0%) 2 (1.0%) 2 (1.0%) 3 (1.5%) 2 (1.0%) 4 (2.0%) 2 (1.0%) 4 (2.0%) 0 (0.0%) 0 (0.0%)
Day 21–179 18 (8.8%) 8 (4.0%) 16 (8.1%) 9 (4.5%) 9 (4.5%) 19 (9.5%) 5 (2.5%) 10 (5.1%) 15 (7.5%) 3 (1.5%)
  1. All participants received inactivated trivalent influenza vaccine, non-adjuvanted (≥65 years and 18–40 years) or formulated with an adjuvant. AS03 is a squalene and α-tocopherol oil-in-water emulsion-based Adjuvant System, with tocopherol content 11.86 mg (A), 5.93 mg (B), or 2.97 mg (C); MPL is 3-O-desacyl-4’- monophosphoryl lipid A: 25 μg (MPL-25) or 50 μg (MPL-50).